RecruitingEndogenous Cushing SyndromeAdrenal InsufficiencyHypercortisolism
A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid Replacement
Eligible age
18–75 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The major goal of this study is to determine the incidence of adrenal insufficiency in patients with endogenous Cushing syndrome receiving osilodrostat treatment combined with a replacement of glucocorticoid (block-and-replace approach). The investigators are also evaluating new biomarker steroids to reflect adequate osilodrostat dosing, the durability and safety, and clinical improvement during treatment.
Sponsor: University of Michigan
You may qualify if…
- ✓ Endogenous Cushing syndrome, either following surgery or not candidates for surgery
- ✓ Under consideration to receive osilodrostat as part of their clinical care
- ✓ Able to provide informed consent.
You may not qualify if…
- ✕ Treatment with other investigational drugs within 30 days or five half-lives (whichever is longer).
- ✕ A history of hypersensitivity to osilodrostat or therapies of a similar chemical class.
Where it's recruiting
Michigan
Ann Arbor
Source: ClinicalTrials.gov · NCT06430528 · last updated 2026-09-09